University Health Network

🇨🇦Canada

Country: 🇨🇦Canada

Ownership: Private

Established: 1999-01-01

Employees: 10K

Market Cap: -

Website: http://www.uhn.ca

Clinical Trials

Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer

Phase 1

Active, not recruiting

Conditions: Recurrent Ovarian Cancer
Recurrent Uterine Cancer
Advanced Cancer
Metastatic Cancer

Interventions: Drug: RP-6306
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2023-10-30

Last Posted Date: 2024-03-22

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 24

Registration Number: NCT06107868

Locations: 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Pilot Study on Trametinib for Surgical Unruptured AVMs

Phase 2

Recruiting

Conditions: Arteriovenous Malformations

Interventions: Drug: Trametinib tablet

First Posted Date: 2023-10-25

Last Posted Date: 2024-05-30

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 10

Registration Number: NCT06098872

Locations: 🇨🇦
University Health Network, Toronto, Ontario, Canada

Effects of Peripheral Electrical Stimulation With Focused Ultrasound on Motor Symptoms in Parkinson's Patients

Not Applicable

Recruiting

Conditions: Parkinson Disease

Interventions: Device: Real TUS
Device: Real FES
Device: Sham FES
Device: Sham TUS

First Posted Date: 2023-10-19

Last Posted Date: 2023-10-19

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 15

Registration Number: NCT06090292

Locations: 🇨🇦
Toronto Western Hospital, Toronto, Ontario, Canada

HN-BIO: A Study of Head and Neck MRI and Tumor Microenvironment Biomarkers

Not Applicable

Recruiting

Conditions: Squamous Cell Carcinoma of Head and Neck

Interventions: Other: fMRI
Other: Oral Pimonidazole

First Posted Date: 2023-10-17

Last Posted Date: 2024-02-07

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 60

Registration Number: NCT06085781

Locations: 🇨🇦
Princess Margaret Cancer Center, Toronto, Ontario, Canada

Sentinel lympH Node Biopsy With Indocyanine Green in Breast Cancer After NEoadjuvant Chemotherapy (SHINE)

Not Applicable

Recruiting

Conditions: Breast Cancer

Interventions: Procedure: ICG guided sentinel lymph node biopsy

First Posted Date: 2023-10-16

Last Posted Date: 2024-05-08

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 100

Registration Number: NCT06085274

Locations: 🇨🇦
University Health Network, Toronto, Ontario, Canada

Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Grade 1 Cancer of the Endometrium

Phase 2

Not yet recruiting

Conditions: Endometrial Cancer
Atypical Hyperplasia

Interventions: Drug: Mirena
Drug: Mounjaro

First Posted Date: 2023-10-10

Last Posted Date: 2024-03-19

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 108

Registration Number: NCT06073184

Effectiveness of Rehabilitation in Adults Suffering From Persistent Concussion Symptoms

Not Applicable

Recruiting

Conditions: Mild Traumatic Brain Injury
Postconcussion Syndrome

Interventions: Other: Non-pharmacological Individualized rehabilitative therapy
Other: Non-pharmacological Usual care therapy

First Posted Date: 2023-10-06

Last Posted Date: 2023-10-06

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 50

Registration Number: NCT06069700

Locations: 🇨🇦
Toronto Rehabilitation Institute, Toronto, Ontario, Canada

Pain Phenotyping in Knee OA: a Pilot Trial

Recruiting

Conditions: Osteo Arthritis Knee
Chronic Post-operative Pain

First Posted Date: 2023-10-04

Last Posted Date: 2023-12-06

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 55

Registration Number: NCT06066684

Locations: 🇨🇦
Toronto Western Hospital, Toronto, Ontario, Canada
🇨🇦
St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada

Durvalumab and Oleclumab in Resectable PDAC

Phase 2

Recruiting

Conditions: Pancreatic Ductal Adenocarcinoma

Interventions: Drug: Durvalumab
Drug: Oleclumab

First Posted Date: 2023-09-29

Last Posted Date: 2024-01-08

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 22

Registration Number: NCT06060405

Locations: 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada

MR-Adaptive Radiation Therapy for Anal Cancer With EScalated-Treatment in a Risk-Optimized Approach

Phase 2

Recruiting

Conditions: Anal Squamous Cell Carcinoma

First Posted Date: 2023-09-22

Last Posted Date: 2024-06-13

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 80

Registration Number: NCT06050707

Locations: 🇺🇸
Medical College of Wisconsin Cancer Center, Milwaukee, Wisconsin, United States
🇦🇺
Austin Health, Heidelberg, Victoria, Australia
🇺🇸
Allegheny Health Network, Pittsburgh, Pennsylvania, United States

and more 1 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy